MATTHEW HAROLD KATZ to Biomarkers, Tumor
This is a "connection" page, showing publications MATTHEW HAROLD KATZ has written about Biomarkers, Tumor.
Connection Strength
0.491
-
Defining and Treating Borderline Resectable Pancreatic Cancer. Curr Treat Options Oncol. 2020 07 28; 21(9):71.
Score: 0.049
-
Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res. 2019 11; 243:90-99.
Score: 0.045
-
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
Score: 0.043
-
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
Score: 0.041
-
Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 11 01; 152(11):1086-1088.
Score: 0.041
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).
Score: 0.039
-
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One. 2017; 12(2):e0171985.
Score: 0.039
-
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
Score: 0.034
-
Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
Score: 0.029
-
ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9. Ann Surg Oncol. 2024 03; 31(3):1842-1843.
Score: 0.016
-
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
Score: 0.016
-
Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma. Hum Pathol. 2023 09; 139:117-125.
Score: 0.015
-
Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer. 2021 06; 124(12):1970-1977.
Score: 0.013
-
Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4615-4622.
Score: 0.013
-
A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget. 2017 Jan 24; 8(4):5885-5894.
Score: 0.010
-
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
Score: 0.009
-
Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS One. 2016; 11(3):e0152300.
Score: 0.009
-
Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol. 2014 Feb; 38(2):147-57.
Score: 0.008
-
Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23.
Score: 0.008
-
SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol. 2014 Mar; 45(3):456-63.
Score: 0.008
-
Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 2013 Feb; 62(3):465-71.
Score: 0.007